Elagolix - Abbvie/Neurocrine

Drug Profile

Elagolix - Abbvie/Neurocrine

Alternative Names: ABT-620; Elagolix sodium; NBI-56418

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Endometriosis
  • Phase III Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 07 Sep 2017 AbbVie plans a phase III trial for Uterine leiomyoma (Combination therapy) in USA and Puerto Rico (NCT03271489)
  • 06 Sep 2017 Preregistration for Endometriosis in USA (PO)
  • 06 Sep 2017 Updated efficacy data from two replicate phase III trials (M12-665 and M12-671) in Endometriosis released by AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top